A Phase 1 Study of Oprozomib to Assess Food Effect, Drug-Drug Interaction With Midazolam, and Safety and Tolerability in Patients With Advanced Malignancies
Latest Information Update: 22 Feb 2021
At a glance
- Drugs Oprozomib (Primary) ; Midazolam
- Indications Haematological malignancies; Multiple myeloma; Solid tumours
- Focus Pharmacokinetics
- Sponsors Amgen
Most Recent Events
- 18 Feb 2021 Status changed to discontinued , according to clinicalTrials.gov record.
- 02 Jul 2019 Planned End Date changed from 12 Jun 2019 to 10 Jul 2019.
- 14 Mar 2019 Planned End Date changed from 30 Jun 2019 to 12 Jun 2019.